Industry: Hospitals & Medical Centers•
Not Specified years
Posted 43 days ago
Postdoctoral Research Fellows in immuno-oncology – Novel cancer immunotherapies
Immunotherapies, such as checkpoint inhibition and adoptive T cell therapies, represent a paradigm shift in the treatment of cancer, inducing impressive responses in diverse malignancies. However, not all patients respond to current immunotherapies and novel therapeutic approaches are needed to circumvent these obstacles.
Postdoctoral Research Fellow positions are available in the Immunotherapy Integrated Research Center at the Fred Hutchinson Cancer Research Center in Seattle, WA. The successful applicants will join a collaborative team that combines clinical research, animal modeling, computational biology and multiplexed immuno-histochemistry to understand the basic mechanisms of antitumor immunity and apply them to the development of novel immunotherapies.
This research program includes the laboratories of: Dr. Aude Chapuis, a translational immuno-oncologist who specializes in adoptive T cell therapies; Dr. Anthony Rongvaux, an immunologist who develops innovative humanized murine models to study the tumor/immune interface; Dr. Raphael Gottardo, a biostatistician with expertise in high-dimensional single cell data analysis; and Dr. Robert Pierce, a pathologist and expert in tumor microenvironment analyses who previously developed tissue-based biomarkers for Merck's anti-PD-1 pembrolizumab antibody.
Our research is focused on understanding the biology and improving clinical outcomes after immune-boosting treatments. Human adoptive immunotherapy trials are initiated and being conducted using the robust Fred Hutch clinical platform. We are performing detailed analysis of patient outcomes to inform next-generation trials. , and developing humanized murine models of checkpoint inhibition and adoptive T cell therapy against solid and liquid cancers. We are using single cell RNA sequencing, genome editing and genomic screens in humanized murine to understand how anti-tumoral immunity functions, why it fails in some patients, and how we can overcome current limitations. We use multiparametric immunohistochemistry to validate humanized mouse results in humans, using a large biorepository of annotated patient specimens.
The scientific questions being addressed include:
The overall objective of this interdisciplinary project is to provide the scientific basis for future clinical trials, leveraging Fred Hutch's continuing leadership in the design, clinical testing and commercialization of successful anticancer drugs and immunotherapies.
Desired skills and experience of the applicants: